1.A Clinical Study of Small Incision Trabeculectomy.
Suk Han KIM ; Dong Won PARK ; Sae Heun RHO
Journal of the Korean Ophthalmological Society 2000;41(12):2603-2610
No Abstract Available.
Trabeculectomy*
2.Phacoemulsification with intraocular posterior chamber lens implantation in the eyes with previous trabeculectomy
Journal of Vietnamese Medicine 2005;0(2):48-54
A prospective study was conducted on 56 patients (56 yes) who underwent trabeculectomy to treat glaucoma and had blurred vision due to cataract. Most patients were 70-80 years old (60.7%). Patients with closed-angle glaucoma were 80.4%. Majority of eyes (42 eyes, 74.8%) had bad visual acuity (<1/10). Postoperatively, 23 eyes (41%) achieved visual acuity from 3/10 to 7/10. Between 1 and 6 months postoperative, visual acuity improved significantly and quite stable during follow-up period with 30 eyes (53.5 %) achieved acuity of 5/10 or better. One month after operation, there were 30 eyes (54.2%) with intraocular pressure<18mmHg and 26 eyes (45.8%) with previous inflammation discharged membrane, disengage or cutting the pupil edge, all are mechanic effects which affect to cornea endothelium and iris
Phacoemulsification
;
Trabeculectomy
3.Trabeculectomy Using a Fornix-based Conjunctival Flap.
Journal of the Korean Ophthalmological Society 1986;27(5):819-922
The safety and success rate of trabeculectomy using fornix-based conjunctival flaps were investigated. Patients with chronic angle-closure glaucoma(22 eyes), primary open-angle glaucoma(10 eyes), secondary glaucoma(4 eyes) and ocular hypertension(1 eye) had a trabeculectomy with a fornix-based conjunctival flap. We analyzed the results of these 37 eyes and compared them witih those of trabeculectomy using a lmbus-based codjunctival flap Trabeculectomy was equally successful(intraocular pressure,
Humans
;
Trabeculectomy*
5.A traction suture holding device for glaucoma procedures
Christopher Cyrille N. Cabrera ; Nilo Vincent d G. FlorCruz II
Philippine Journal of Ophthalmology 2022;47(2):111-114
Objective:
We described an adjustable traction technique for glaucoma surgeries that provided
adequate visualization of the surgical field.
Methods:
A prototype device was designed to provide good exposure of the surgical site by using a
peripheral lamellar trans-corneal suture capable of applying and sustaining tension. Adjustments to
the amount of traction required were made through the device.
Results:
The device was used in 9 cases of glaucoma surgeries: 5 trabeculectomies and 4 glaucoma
drainage device implantations. No significant complications were observed.
Conclusions
The device was easy to use and allowed more flexibility for the surgeon.
Glaucoma
;
Trabeculectomy
6.Study on cataract Phaco operative method, implanting IOL combined with trabeculectomy
Journal of Vietnamese Medicine 2004;297(4):14-18
40 patients (51 eyes, 17 males, 23 females) having cataract combined open or closure angle glaucoma have been operated by Phaco method, implant IOL and trabeculectomy at Ophthalmology Hospital from January to September 2003. The results: Phaco method, implant IOL combined with trabecolectomy have a good effect in regulating IOP. 100% IOP regulated, mean reducing of IOP are 12mmHg. After 6 months periods, no recurrent case of IOP. Post operation, sight improves fast, good and very stable. Sight rate gained 5/10 (66.7%)
Surgery
;
Eye
;
Trabeculectomy
7.The Effect of Mitomycin C on Primary Trabeculectomy: Comparative Study in the Same Person.
Dae Hyun KIM ; Young Ghee LEE ; Young Jae HONG
Journal of the Korean Ophthalmological Society 1998;39(9):2129-2135
No abstract available.
Humans
;
Mitomycin*
;
Trabeculectomy*
8.Low-dose and High-dose of Mitomycin-C in Trabeculectomy.
Jae Jun LEE ; Ki Ho PARK ; Dong Ho YOUN
Journal of the Korean Ophthalmological Society 1996;37(4):622-627
The purpose of this study is to compare the effects of three different concentrations of mitomycin-C(MMC) as an adjunct therapy to trabeculectomy. We reviewed 26 patients(36 eyes) who underwent trabeculectomy in which MMC was applied intraoperatively. The application time was 5 minute, and concentration of MMC was 0.1mg/ml(n=10), 0.2mg/ml(n=17) and 0.41mg/ml(n=9) respectively. The mean IOP at postoperative 3 months was significantly lower in 0.4mg/ml group (10.4 +/- 5.5mmHg) than in the 0.2mg/ml group(16.1 +/- 4.7mmHg)(p<0.05). There was no statistical difference among the three groups in the success rate regardless of medication, the size and longevity of bleb. The postoperative hypotony(2 eyes) was noted in the 0.4mg/ml group. In conclusions, It is desirable to use the lowest concentration of MMC that will facilitate bleb formation.
Blister
;
Longevity
;
Mitomycin*
;
Trabeculectomy*
9.Study on the effects of trabeculectomy surgery with placing 5-fluorouracil saturated gelaspon (5-FU) in treating glaucoma in youth patients
Journal of Practical Medicine 2004;471(1):72-76
At The Central Insititute of Opthtalmology from 10/1998 to 11/2003, Trabeculectomy was conducted on 44 eyes of pediatric geaucoma patients with placing a 5 fluouracyt saturated gelaspon (50mg/ml 5 F.U on 2 x 2mm gelaspon flap) under the diseased eye in 5 minutes, then 5- FU was washed away with Ruiger lactat solution. The surgery was efficacious for treating glaucome in young person and children.
Trabeculectomy
;
Therapeutics
;
Glaucoma
;
Adolescent
10.Topical Bevacizumab as adjunctive therapy for bleb survival after trabeculectomy in the rabbit model
Jaime Rafeal Hubilla Tripon ; Ma. Imelda Yap-Veloso
Philippine Journal of Ophthalmology 2012;37(2):66-72
Objective:
To determine the effect of topically administered bevacizumab on bleb survival and histology after
trabeculectomy in rabbit eyes.
Methods:
This is an experimental interventional comparative animal study. Sixteen rabbit eyes underwent
trabeculectomy, 8 of which were enhanced with intraoperative mitomycin-C. Eyes were randomized to receive
either topical balanced salt solution (BSS) or topical bevacizumab at a concentration of 12.5 mg/mL. Intraocular
pressure, bleb dimensions and vascularity grading were measured. IOP was recorded as a ratio of IOP of the
experimental operated eye divided by the IOP of the contralateral control eye (IOPratio) as a function of time. Bleb
morphology was recorded as a percentage of the maximum estimated bleb volume (% bleb) as a function of time.
Bleb failure occurred if IOPratio ≥0.8, or if % bleb=0. The eyes were then submitted for histopathological analysis
after bleb failure has occurred.
Results:
In plain trabeculectomy, the mean bleb survival in terms of IOP were 6.3 and 9.2 days in the BSS and topical
bevacizumab groups respectively (ρ=0.25). In mitomycin-C-enhanced trabeculectomy, the mean bleb survival was
16 and 18.2 days respectively (ρ=0.40). In plain trabeculectomy, mean bleb survival in terms of bleb morphology
were 8 and 12.2 days for the BSS and bevacizumab groups respectively (ρ=0.08). In enhanced trabeculectomy, mean
bleb survival were 19.5 and 20 days respectively (ρ=0.99). Mean vascularity grading were 2 and 1.9 for the BSS
groups, and 1.6 and 1.4 for the bevacizumab groups.
Conclusion
Topical bevacizumab as adjunctive therapy after trabeculectomy, whether plain or enhanced with
mitomycin-C, showed a trend towards prolonged bleb survival, even though the results of this study were not
statistically significant.
Bevacizumab
;
Trabeculectomy
;
Mitomycin